NARA Discovery
Article Details
← Back to Search Results
Journal Article

Phenotypic screening in Organ-on-a-Chip systems: a 1537 kinase inhibitor library screen on a 3D angiogenesis assay

Camilla Soragni; Karla Queiroz; Chee Ping Ng; Arthur Stok; Thomas Olivier; Dora Tzagkaraki; Jeroen Heijmans; Johnny Suijker; Sander P. M. de Ruiter; Aleksandra Olczyk; Marleen Bokkers; Frederik Schavemaker; Sebastian J. Trietsch; Henriëtte L. Lanz; Paul Vulto; Jos Joore
Angiogenesis · Vol. 27, Issue 1 · pp. 37-49 · 2024

Abstract

Modern drug development increasingly requires comprehensive models that can be utilized in the earliest stages of compound and target discovery. Here we report a phenotypic screening exercise in a high-throughput Organ-on-a-Chip setup. We assessed the inhibitory effect of 1537 protein kinase inhibitors in an angiogenesis assay. Over 4000 micro-vessels were grown under perfusion flow in microfluidic chips, exposed to a cocktail of pro-angiogenic factors and subsequently exposed to the respective kinase inhibitors. Efficacy of compounds was evaluated by reduced angiogenic sprouting, whereas reduced integrity of the main micro-vessel was taken as a measure for toxicity. The screen yielded 53 hits with high anti-angiogenicity and low toxicity, of which 44 were previously unassociated with angiogenic pathways. This study demonstrates that Organ-on-a-Chip models can be screened in high numbers to identify novel compounds and targets. This will ultimately reduce bias in early-stage drug development and increases probability to identify first in class compounds and targets for today’s intractable diseases.

Bibliographic Information

JournalAngiogenesis
PublisherSpringer
Publication Date2024-02-01
Publication Year2024
Volume27
Issue1
Pages37-49
Document TypeJournal Article
eISSN1573-7209
DOI10.1007/s10456-023-09888-3

Access Information

NARA Access Coverage1997-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10456
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.